These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31125485)

  • 21. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection.
    Altfeld M; Addo MM; Rosenberg ES; Hecht FM; Lee PK; Vogel M; Yu XG; Draenert R; Johnston MN; Strick D; Allen TM; Feeney ME; Kahn JO; Sekaly RP; Levy JA; Rockstroh JK; Goulder PJ; Walker BD
    AIDS; 2003 Dec; 17(18):2581-91. PubMed ID: 14685052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects.
    King D; Tomkins S; Waters A; Easterbrook PJ; Thurmond LM; Thorborn DE; Raffi F; Kemeny DM; Vyakarnam A
    J Allergy Clin Immunol; 2005 May; 115(5):1081-7. PubMed ID: 15867870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV.
    Quiros-Roldan E; Gardini G; Properzi M; Ferraresi A; Carella G; Marchi A; Malagoli A; Focà E; Castelli F
    Pharmacogenet Genomics; 2020 Oct; 30(8):167-174. PubMed ID: 32453265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms involved in the Abacavir-mediated hypersensitivity syndrome.
    Llano A; Brander C
    Cell Res; 2012 Dec; 22(12):1637-9. PubMed ID: 22777424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients.
    Moragas M; Belloso WH; Baquedano MS; Gutierrez MI; Bissio E; Larriba JM; Fay F; Aulicino P; Gurevich JM; Yaunguzian MF; Maldonado AC; Falistocco C; Sen L; Mangano A
    Tissue Antigens; 2015 Jul; 86(1):28-31. PubMed ID: 25922880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlates of spontaneous viral control among long-term survivors of perinatal HIV-1 infection expressing human leukocyte antigen-B57.
    Tang Y; Huang S; Dunkley-Thompson J; Steel-Duncan JC; Ryland EG; St John MA; Hazra R; Christie CD; Feeney ME
    AIDS; 2010 Jun; 24(10):1425-35. PubMed ID: 20539088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exuberant Positive Patch Test to Abacavir in a Patient with the HLA-B*5701 Haplotype.
    Micozzi S; Rojas P; Rodriguez-Gamboa A; De Barrio M
    J Allergy Clin Immunol Pract; 2015; 3(6):965-7. PubMed ID: 26116952
    [No Abstract]   [Full Text] [Related]  

  • 28. Avidity determines T-cell reactivity in abacavir hypersensitivity.
    Adam J; Eriksson KK; Schnyder B; Fontana S; Pichler WJ; Yerly D
    Eur J Immunol; 2012 Jul; 42(7):1706-16. PubMed ID: 22585534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance].
    Arnedo Valero M
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():34-9. PubMed ID: 18680694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivity.
    Cardone M; Garcia K; Tilahun ME; Boyd LF; Gebreyohannes S; Yano M; Roderiquez G; Akue AD; Juengst L; Mattson E; Ananthula S; Natarajan K; Puig M; Margulies DH; Norcross MA
    J Clin Invest; 2018 Jul; 128(7):2819-2832. PubMed ID: 29782330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection.
    Chen H; Ndhlovu ZM; Liu D; Porter LC; Fang JW; Darko S; Brockman MA; Miura T; Brumme ZL; Schneidewind A; Piechocka-Trocha A; Cesa KT; Sela J; Cung TD; Toth I; Pereyra F; Yu XG; Douek DC; Kaufmann DE; Allen TM; Walker BD
    Nat Immunol; 2012 Jun; 13(7):691-700. PubMed ID: 22683743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The frequency of HLA-B(∗)57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica.
    Arrieta-Bolaños E; Madrigal JA; Marsh SG; Shaw BE; Salazar-Sánchez L
    Hum Immunol; 2014 Nov; 75(11):1092-6. PubMed ID: 25286002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HLA- B*5701 Allele in HIV-infected Indian Children and its Association with Abacavir Hypersensitivity.
    Manglani MV; Gabhale YR; Lala MM; Sekhar R; More D
    Indian Pediatr; 2018 Feb; 55(2):140-141. PubMed ID: 29242412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
    Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR
    Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
    Waters LJ; Mandalia S; Gazzard B; Nelson M
    AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. External quality assessment of patient HLA-B*57:01 testing prior to abacavir prescription.
    Darke C; Corbin SA
    Int J Immunogenet; 2014 Aug; 41(4):277-80. PubMed ID: 24762294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Role of Conformational Dynamics in Abacavir-Induced Hypersensitivity Syndrome.
    Fodor J; Riley BT; Kass I; Buckle AM; Borg NA
    Sci Rep; 2019 Jul; 9(1):10523. PubMed ID: 31324847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful translation of pharmacogenetics into the clinic: the abacavir example.
    Phillips E; Mallal S
    Mol Diagn Ther; 2009; 13(1):1-9. PubMed ID: 19351209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.
    Hetherington S; Hughes AR; Mosteller M; Shortino D; Baker KL; Spreen W; Lai E; Davies K; Handley A; Dow DJ; Fling ME; Stocum M; Bowman C; Thurmond LM; Roses AD
    Lancet; 2002 Mar; 359(9312):1121-2. PubMed ID: 11943262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful implementation of a national HLA-B*5701 genetic testing service in Canada.
    Lalonde RG; Thomas R; Rachlis A; Gill MJ; Roger M; Angel JB; Smith G; Higgins N; Trottier B
    Tissue Antigens; 2010 Jan; 75(1):12-8. PubMed ID: 19843279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.